CircRNA signature predicts immunotherapy response in advanced non-small cell lung cancer.

ABSTRACT:

Background

Immune checkpoint inhibitors (ICIs) offer significant benefits for advanced non-small cell lung cancer (NSCLC) but yield objective response rates of only 10%-30% in unselected patients. Circular RNAs (circRNAs), implicated in cancer RNA dysregulation, may serve as biomarkers for ICI response.

Objectives

Identify circRNA signature to predict atezolizumab efficacy of NSCLC.

Design

This study analyzed circRNA expression profiles from 891 advanced NSCLC patients in the OAK and POPLAR clinical studies.

Methods

Based on The Cancer CircRNA Immunome Atlas database, we identified circRNAs associated with the efficacy of immunotherapy in NSCLC patients. Then, we establish predictive models for immunotherapy efficacy using multiple methods and conduct performan

SUBMITTER: Li X 

PROVIDER: S-EPMC12647551 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature